Gilead Sciences is a large American biotech company that researches, develops, and sells drugs. Its filings show it lobbies Congress mostly on Medicare and Medicaid and other health issues, including education about access to HIV medicines and the 340B drug discount program, and on implementation of parts of the Inflation Reduction Act. It hired W Strategies, LLC and reported about $240,000 in lobbying through January 21, 2026.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
DARREN WILLCOX
The latest disclosures for this client.
W STRATEGIES, LLC
Q1W STRATEGIES, LLC
Q4The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
W STRATEGIES, LLC
W STRATEGIES, LLC
Q3W STRATEGIES, LLC
Q2W STRATEGIES, LLC
Q1